Trexquant Investment LP Purchases 1,289 Shares of Thermo Fisher Scientific Inc. (TMO)
Trexquant Investment LP lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,340 shares of the medical research company’s stock after purchasing an additional 1,289 shares during the period. Trexquant Investment LP’s holdings in Thermo Fisher Scientific were worth $1,578,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of TMO. Proficio Capital Partners LLC raised its holdings in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $113,000. Chicago Partners Investment Group LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $108,000. Ropes Wealth Advisors LLC raised its holdings in Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $138,000. 86.16% of the stock is currently owned by institutional investors and hedge funds.
TMO has been the topic of several recent analyst reports. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen reaffirmed a “buy” rating and issued a $200.00 price target on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Morgan Stanley reaffirmed an “overweight” rating and issued a $220.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target on the stock in a report on Thursday, September 7th. Finally, Barclays reaffirmed an “overweight” rating and issued a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $205.21.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the previous year, the firm earned $2.03 earnings per share. The firm’s revenue for the quarter was up 13.9% compared to the same quarter last year. equities research analysts predict that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s payout ratio is 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares in the company, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.49% of the stock is owned by insiders.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Stock Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related stocks with our FREE daily email newsletter.